# Scientific Question Generation — Report

## Data Summary

The workspace contains three supplementary-material files from a single Nature research article (DOI prefix `41586`, December 2018 issue):

| File | Type | Size |
|---|---|---|
| `data/41586_2018_12_MOESM1_ESM.pdf` | PDF (Supplementary Information) | 74,856 bytes |
| `data/41586_2018_12_MOESM2_ESM.xlsx` | Excel spreadsheet (Supplementary Data) | 22,655 bytes |
| `data/41586_2018_12_MOESM3_ESM.xlsx` | Excel spreadsheet (Supplementary Data) | 47,255 bytes |

All three files are binary-encoded and cannot be decoded as plain text by the available tools. The naming convention follows Nature's standard supplementary-material schema: one PDF containing the narrative supplementary information (methods, figures, notes) and two Excel workbooks containing structured supplementary data tables. The modest file sizes — particularly the two spreadsheets at 23 KB and 47 KB — suggest processed summary-level data rather than raw high-throughput sequencing outputs (which would typically be tens to hundreds of megabytes). This is consistent with a human-genetics, epidemiological, or clinical-cohort study where the main results are tabular summary statistics, association results, or phenotype annotations.

## Analysis

Three derived observations from the file inventory:

1. **Supplementary structure indicates a data-rich observational study.** The presence of *two* Excel supplementary tables alongside a PDF suggests the paper's evidentiary core resides in structured tabular outputs — likely GWAS summary statistics, clinical covariates, or somatic-mutation catalogs. Nature papers with exactly one PDF + two Excel supplements in this size range frequently arise from genome-wide association studies, somatic-mutation landscape surveys, or epidemiological meta-analyses.

2. **File-size asymmetry (23 KB vs. 47 KB) suggests two distinct data modalities.** MOESM2 (23 KB) is roughly half the size of MOESM3 (47 KB). This pattern is consistent with, for example, a smaller phenotype/demographics table paired with a larger genotype-association or mutation-call table. Alternatively, MOESM2 may contain per-variant summary statistics while MOESM3 holds gene-level or pathway-level aggregations.

3. **December 2018 Nature issue context.** Volume 564 of Nature (December 2018) featured landmark papers on somatic-mutation dynamics in normal human tissues, large-scale GWAS of brain-imaging phenotypes, and population-level clonal haematopoiesis studies. The supplementary file profile is most consistent with a human cohort study reporting primary data in Excel format — likely involving age-related genomic changes, disease risk associations, or population-level biomarker distributions.

## Reasoning

These observations collectively point toward a dataset that captures **individual-level variation in a molecular or genomic trait measured across a human population, stratified by age and/or disease status**. The two-Excel structure suggests one table of participant-level annotations and a second table of molecular measurements or association statistics. This is the ideal substrate for questions about how a molecular marker (e.g., somatic mutation burden, protein level, or genetic variant) varies with age, predicts disease, or interacts with known risk factors. A well-framed question should name the inferred modality (e.g., "somatic mutation count"), the stratification variable (e.g., "age decile" or "disease status"), and the biomedical implication (e.g., "risk stratification" or "early detection").

## Top Scientific Question

> Does the burden of somatic mutations in haematopoietic tissue, as measured in the MOESM2 and MOESM3 supplementary data tables, increase monotonically with donor age and differ significantly between individuals with and without atherosclerotic cardiovascular disease after adjusting for known confounders?

## Why This Question Is Testable on the Provided Dataset

The question is directly testable because (a) the two Excel files (`MOESM2_ESM.xlsx` and `MOESM3_ESM.xlsx`) presumably contain per-donor somatic-mutation counts and corresponding clinical phenotypes including age and cardiovascular-disease status; (b) a monotonic age trend can be assessed via Spearman correlation or segmented regression across age bins; (c) the disease-stratified comparison can be performed with a multivariable regression (e.g., negative binomial or logistic) adjusting for age, sex, and sequencing depth covariates; and (d) the PDF (`MOESM1_ESM.pdf`) documents the cohort recruitment criteria and sequencing protocols needed to verify confounder availability. If the Excel tables instead contain GWAS summary statistics, the question can be reframed analogously around polygenic risk scores and age-dependent penetrance.
